KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema

Reuters

2025/10/07

KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema $(HAE)$. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2573684988"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573684988\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573684988?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 04:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573684988","market":"nz","top_or_hot":-1,"title":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-07 04:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema <a href=\"https://laohu8.com/S/HAE\">$(HAE)$</a>. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/KALV\">Kalvista Pharmaceuticals Inc</a>. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KALV","symbol_name":"Kalvista Pharmaceuticals Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDLc1k6wY:1","article_id":"2573684988","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573684988","pubTimestamp":1759780818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY, the First Oral On-Demand Treatment for Hereditary Angioedema. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on October 06, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KALV":"Kalvista Pharmaceuticals Inc","BK4139":"生物科技"},"translate_title":"KalVista Pharmaceuticals宣布EKTERLY的积极临床数据和欧洲上市®，首个口服按需治疗遗传性血管性水肿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KALV":0.9},"content_text":"KalVista Pharmaceuticals Announces Positive Clinical Data and European Launch of EKTERLY®, the First Oral On-Demand Treatment for Hereditary Angioedema\n    \n\n        KalVista Pharmaceuticals Inc. has announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first oral on-demand treatment for hereditary angioedema $(HAE)$. The findings were presented at the 20th German Allergy Congress in Düsseldorf, Germany, held from October 2-4, 2025. Results from the studies demonstrated that sebetralstat enabled rapid and effective treatment of HAE attacks among European participants, with a median time to treatment of 16 minutes and a median time to beginning of symptom relief of 1.6 hours. The KONFIDENT-S interim analysis included 69 participants from 15 European countries who collectively treated 999 attacks. The data also highlighted barriers associated with injectable therapies, such as injection-site reactions and difficulty accessing medication, based on a patient survey. EKTERLY is now approved in the European Union, with a launch planned in Germany this quarter and additional European launches expected in 2026 and beyond.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251006039455) on October 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}